Thromb Haemost 1992; 68(05): 495-499
DOI: 10.1055/s-0038-1646306
Original Article
Schattauer GmbH Stuttgart

Prolonged Bleeding Time in Patients with Lupus Anticoagulant

E Orlando
The Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
,
S Cortelazzo
The Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
,
M Marchetti
The Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
,
R Sanfratello
The Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
,
T Barbui
The Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
› Author Affiliations
Further Information

Publication History

Received 23 January 1992

Accepted after revision 10 June 1992

Publication Date:
04 July 2018 (online)

Summary

Platelet adhesion to collagen under flow conditions was studied in 18 patients with lupus anticoagulant, seven of which showed a prolonged bleeding time in the presence of a normal platelet count. The effect of patient plasma, IgG and purified anticardiolipin antibodies on platelet adhesion was also examined. We found a significant reduction of platelet adhesion in patients with lupus anticoagulant, which was more evident in patients with prolonged bleeding time. This platelet adhesion defect could be attributed to a plasma factor. In fact, patients' platelets regained normal adhesion when mixed with normal plasma, whereas controls' platelets showed abnormal adhesion in the presence of patient plasma. A causative role of antiphospholipid antibodies was demonstrated in experiments using purified immunoglobulins and anticardiolipin antibodies.

 
  • REFERENCES

  • 1 Much JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 1980; 92: 156-160
  • 2 Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9
  • 3 Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticar-diolipin antibodies (ACA), directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547
  • 4 Bevers EM, Comfurius P, van Rijn JLML, Hemker HC, Zwaal RFA. Generation of prothrombin converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem 1982; 122: 429-436
  • 5 Harris EN, Asherson RA, Gharavi AE, Morgan SH, Derue G, Hughes GRV. Thrombocytopenia in SLE and related autoimmune disorders - Association with anticardiolipin antibodies. Br J Haematol 1985; 59: 227-230
  • 6 Coehn AJ, Philips TM, Kessler CM. Circulating coagulation inhibitors in the Acquired Immunodeficiency Syndrome. Ann Intern Med 1986; 104: 175-180
  • 7 Galli M, Béguin S, Lindhout T, Hemker CH. Inhibition of phospholipid and platelet-dependent prothrombinase activity in the plasma of patients with lupus anticoagulant. Br J Haematol 1989; 72: 549-555
  • 8 Galli M, Cortelazzo S, Viero P, Finazzi G, de Gaetano G, Barbui T. Interaction between platelets and lupus anticoagulant. Eur J Haematol 1988; 41: 88-94
  • 9 Exner T, Rickard A, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978; 40: 143-151
  • 10 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russel viper venom time for the diagnosis of lupus anticoagulant. Blood 1986; 68: 869-874
  • 11 Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemostas 1991; 65: 320-322
  • 12 Loizou S, McCrea JD, Rudge A, Reynolds R, Boyle CE, Harris EN. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunoadsorbent assay (ELISA): standardization and quantification of results. Clin Exp Immunol 1985; 62: 738-744
  • 13 Pengo V, Thiagarajan P, Shapiro SS, Hein MJ. Immunological specificity and mechanism of action of IgG lupus anticoagulant. Blood 1987; 70: 69-76
  • 14 Sakariassen KB, Bolhuis PA, Sixma JJ. Adhesion of human blood platelets to human artery subendothelium is mediated by factor VIII-von Willebrand factor bound to subendothelium. Nature 1979; 279: 636-638
  • 15 Sakariassen KS, Aarts PAMM, de Groot PG, Houdijk WPM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med 1983; 102: 522-535
  • 16 Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 1973; 5: 167-179
  • 17 Zwaginga JJ, Sixma JJ, de Groot PG. Activation of endothelial cells induces platelet thrombus formation on their matrix. Arteriosclerosis 1990; 10: 49-61
  • 18 Lechner K. Lupus anticoagulant and thrombosis. In: Thrombosis and Haemostasis 1987. Verstraete M, Vermylen J, Lijnen HR, Arnout J. (eds) International Society on Thrombosis and Haemostasis and. Leuven University Press, Leuven: 1987. p 525
  • 19 Gastineau DA, Kazmier FJ, Nichols WL, Bowie EJW. Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Am J Hematol 1985; 19: 265-275
  • 20 Hasselaar P, Derksen RHWM, Blokzijl L, Hessing M, Nieuwenhuis HK, Bouma BN, de Groot PG. Risk factors for thrombosis in lupus patients. Ann Rheum Dis 1989; 48: 933-940